JAK2 inhibitor TQ05105
Term · Oncology and biomedicine · MLC-T-ONC-014618
An orally bioavailable inhibitor of Janus-associated kinase 2 (JAK2), with potential antineoplastic activity. Upon oral administration, JAK2 inhibitor TQ05105 inhibits JAK2 activity, thereby preventing the activation of the JAK/STAT (signal transducer and activator of transcription) signaling pathway and the activation of STAT3. This may lead to an induction of tumor cell apoptosis and a decrease in tumor cell proliferation. JAK2, often upregulated or mutated in a variety of cancer cells, mediates STAT3 activation and plays a key role in tumor cell proliferation and survival.
| Identifier | MLC-T-ONC-014618 |
|---|---|
| Field | Oncology and biomedicine |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-014618",
"term": "JAK2 inhibitor TQ05105",
"field": "Oncology and biomedicine",
"definition": "An orally bioavailable inhibitor of Janus-associated kinase 2 (JAK2), with potential antineoplastic activity. Upon oral administration, JAK2 inhibitor TQ05105 inhibits JAK2 activity, thereby preventing the activation of the JAK/STAT (signal transducer and activator of transcription) signaling pathway and the activation of STAT3. This may lead to an induction of tumor cell apoptosis and a decrease in tumor cell proliferation. JAK2, often upregulated or mutated in a variety of cancer cells, mediates STAT3 activation and plays a key role in tumor cell proliferation and survival.",
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/jak2-inhibitor-tq05105/"
}
Record 9,676 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.